{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:49:15Z","timestamp":1790603355893,"version":"4.1.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.2967\/jnumed.124.268345","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:20:20Z","timestamp":1738254020000},"page":"391-397","source":"Crossref","is-referenced-by-count":8,"title":["Side-by-Side Comparison of the In\u00a0Vivo Performance of [<sup>212<\/sup>Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds"],"prefix":"10.2967","volume":"66","author":[{"given":"Amal","family":"Saidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania A.","family":"Stallons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy G.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Schatzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien J.","family":"Torgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025030410451223000_66.3.391.1","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.3390\/jcm12155138","article-title":"A comprehensive review on neuroendocrine neoplasms: presentation, pathophysiology and management","volume":"12","author":"Sultana","year":"2023","journal-title":"J Clin Med."},{"key":"2025030410451223000_66.3.391.2","unstructured":"Radiomedix Inc. Phase 1 study of AlphaMedix\u2122 in adult subjects with SSTR (+) NET. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT03466216. Published August 24, 2021. Accessed January 9, 2025."},{"key":"2025030410451223000_66.3.391.3","unstructured":"Advanced Accelerator Applications. A study comparing treatment with 177Lu-DOTA0-Tyr3-octreotate to octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours (NETTER-1). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT01578239. Published April 4, 2022. Accessed January 9, 2025."},{"key":"2025030410451223000_66.3.391.4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2806"},{"key":"2025030410451223000_66.3.391.5","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2024.42.16_suppl.4020","article-title":"Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): a phase 2 study","volume":"42","author":"Strosberg","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025030410451223000_66.3.391.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263230"},{"key":"2025030410451223000_66.3.391.7","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1103"},{"key":"2025030410451223000_66.3.391.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.091165"},{"key":"2025030410451223000_66.3.391.9","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050034"},{"key":"2025030410451223000_66.3.391.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.250274"},{"key":"2025030410451223000_66.3.391.11","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21434"},{"key":"2025030410451223000_66.3.391.12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0026-895X(25)09370-8","article-title":"Identification and characterization of novel somatostatin antagonists","volume":"50","author":"Bass","year":"1996","journal-title":"Mol Pharmacol."},{"key":"2025030410451223000_66.3.391.13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/pharmaceutics14010189","article-title":"212Pb: production approaches and targeted therapy applications","volume":"14","author":"Kokov","year":"2022","journal-title":"Pharmaceutics."},{"key":"2025030410451223000_66.3.391.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(99)00086-4"},{"key":"2025030410451223000_66.3.391.15","unstructured":"Schultz MK Pigge C Li M Gabr M Sagastume E , University of Iowa Research Foundation UIRF, assignee. Compositions for chelating metals at low temperatures. Patent application CA3098492A1. Published December 19, 2019."},{"key":"2025030410451223000_66.3.391.16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.apradiso.2017.05.006","article-title":"Automated cassette-based production of high specific activity [203\/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer","volume":"127","author":"Li","year":"2017","journal-title":"Appl Radiat Isot."},{"key":"2025030410451223000_66.3.391.17","doi-asserted-by":"crossref","first-page":"109362","DOI":"10.1016\/j.apradiso.2020.109362","article-title":"Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples","volume":"166","author":"Napoli","year":"2020","journal-title":"Appl Radiat Isot."},{"key":"2025030410451223000_66.3.391.18","doi-asserted-by":"crossref","first-page":"110473","DOI":"10.1016\/j.apradiso.2022.110473","article-title":"Primary standardization of 212Pb activity by liquid scintillation counting","volume":"190","author":"Bergeron","year":"2022","journal-title":"Appl Radiat Isot."},{"key":"2025030410451223000_66.3.391.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.137182"},{"key":"2025030410451223000_66.3.391.20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41181-023-00197-0","article-title":"First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs","volume":"8","author":"Handula","year":"2023","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2025030410451223000_66.3.391.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05564-0"},{"key":"2025030410451223000_66.3.391.22","doi-asserted-by":"crossref","first-page":"e76823","DOI":"10.7554\/eLife.76823","article-title":"Cryo-EM structure of the human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand-binding specificity","volume":"11","author":"Heo","year":"2022","journal-title":"Elife."},{"key":"2025030410451223000_66.3.391.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.205161"},{"key":"2025030410451223000_66.3.391.24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-023-06494-9","article-title":"Structural modifications toward improved lead-203\/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors","volume":"51","author":"Lee","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451223000_66.3.391.25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph16050674","article-title":"Peptide radioligands in cancer theranostics: agonists and antagonists","volume":"16","author":"Nock","year":"2023","journal-title":"Pharmaceuticals."},{"key":"2025030410451223000_66.3.391.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.138834"},{"key":"2025030410451223000_66.3.391.27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3390\/pharmaceutics15020414","article-title":"Preclinical evaluation of a lead specific chelator (PSC) conjugated to radiopeptides for 203Pb and 212Pb-based theranostics","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics."},{"key":"2025030410451223000_66.3.391.28","unstructured":"Lee D Schultz MK Li M .; University of Iowa Research Foundation UIRF, assignee. Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers. Patent application WO2021154921A1. Published August 5, 2021."},{"key":"2025030410451223000_66.3.391.29","unstructured":"Lee D Li M Liu D . A multi-dosing strategy improves the efficacy of SSTR2-targeted alpha-particle therapy for neuroendocrine tumors with a low toxicity profile. University of Iowa website. https:\/\/netrf.org\/wp-content\/uploads\/2020\/12\/1605289424-3-Lee-Poster.pdf. Published December 21, 2020. Accessed January 9, 2025."},{"key":"2025030410451223000_66.3.391.30","unstructured":"Lee DA Li MB Liu DC . Evaluation of renal and hematologic toxicities of 212Pb-VMT-alpha-NET to inform the safety of alpha-particle therapy for neuroendocrine tumors. Paper presented at: 18th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. Vol. 33. Wiley; 2021:190."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:46:03Z","timestamp":1741113963000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.2967\/jnumed.124.268345"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268345","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}